成人午夜又粗又硬又长_鲁一鲁AV2019在线_欧美深深色噜噜狠狠yyy_www.91色.com_色影音先锋av资源网_特级做A爰片久久毛片A片喷水_99精品无人区乱码1区2区3区_国产人妻久久精品一区_欧美午夜精品久久久久久浪潮_av免费无码天堂在线_蜜桃色欲AV久久无码精品软件_日美一级毛片_久久久久久久久性潮_国产乱对白精彩_日韩精品免费一区二区_亚洲欧美精品在线_无码国产69精品久久久久_开心五月综合激情综合五月_干一夜综合_亚洲中文有码字幕日本

    隨著倫敦生物技術公司Circassia宣布開始進行總額達3億3千2百萬美元的IPO，打破了英國生物技術公司IPO記錄。這是否意味著2013年美國發生的生物技術公司IPO狂潮將漂洋過海登陸歐洲大陸？
    據報道，目前AC Immune公司和Molecular Partners公司都已經加入了IPO的隊列，并已經受到了歐洲投資者的廣泛關注。而瑞士的Novimmune、法國的Oncodesign、GenomicVision等公司也正在考慮是否加入IPO的行列。
    事實上此前歐洲生物技術公司大多選擇不在本土上市，而是進軍美國納斯達克市場。不過隨著Circassia公司的成功，是否會有越來越多的生物技術公司選擇在歐洲市場進行募資尚未可知。
    詳細英文報道：
    With London biotech Circassia clearing about $332 million in a record-breaking U.K. IPO, a spate of other European life sciences outfits sit stage left with eyes on the public markets, stoking hopes that the stateside fervor over drug developers could cross the ocean and line their pockets.
    As Reuters reports, European bankers, bankrollers and biotechs are optimistic Circassia's success is a sign of things to come, pointing to AC Immune and Molecular Partners as potential next entrants onto the IPO scene. For AC Immune, its fortunes are closely linked to some soon-to-come Phase II results for the Alzheimer's treatment crenezumab, and Reuters' sources figure the biotech may swing for a public debut if the drug performs well. Molecular Partners, on the other hand, is already a revenue-generating operation, most recently licensing its drug-delivery technology to Roche ($RHHBY).
    And the list goes on: Switzerland's Novimmune may consider a float this year, while smaller French outfits Oncodesign, Genomic Vision and Genticel are said to be eyeing Euronext IPOs.
    "There is growing noise suggesting the IPO market is opening up in Europe and, in fact, it would be surprising if it didn't," Index Ventures' Francesco De Rubertis told Reuters. "There is normally a lag of about a year from the U.S. taking off and Europe following."
    But despite mounting continental optimism, there are deep-seated differences between markets overseas and in the U.S. America's wide pool of biotech companies has spawned a complementary horde of specialist funds and investors who understand the business and are willing to make risky bets on drug development. Europe, by contrast, is driven more by generalist backers, and many investors have been slow to forget burst bubbles past, according to Reuters.
    As such, as the U.S. market for biotech IPOs exceeded hyperbole over the past year, many overseas life sciences companies have chosen to make their market debuts on the Nasdaq instead of at home. The Netherlands-based UniQure ($QURE) pulled off one of the most successful U.S. IPOs of this year, and the promising U.K. medical device outfit Lombard Medical is plotting to make its $80 million first offering in America.
    But money has a way of changing people's minds, and a few more high-dollar success stories like Circassia may lead investors across Europe to give biotech another shot.
    "The market is receptive to good companies that have got a well thought out story," Circassia CEO Steve Harris told Reuters. "I don't know that there will be a lot, but I'm sure there are a number of other good quality companies that will come to market in Europe."